Preclinical studies have shown that treatment with exogenous type I IFN or STING or RIG-I agonists, which induce IFN production, can lower the viral load if given prophylactically [81–83, 141]; however, this effect on viral load is limited once infection is established [142]. This evidence concerns the gene STING1 and infection.